C12N 2999/002
Adverse teaching
C12N2999/002 (Adverse teaching) appears on 4 US grants and 7 published applications in this corpus.
Search patents in C12N- Granted patents
- 4
- Published applications
- 7
- Assignees
- 4
- Inventors
- 18
- Latest grant
- 1 Apr 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2013 | 0 | 1 |
| 2014 | 0 | 1 |
| 2015 | 0 | 1 |
| 2016 | 0 | 1 |
| 2017 | 0 | 0 |
| 2018 | 0 | 0 |
| 2019 | 1 | 0 |
| 2020 | 1 | 1 |
| 2021 | 0 | 0 |
| 2022 | 0 | 0 |
| 2023 | 1 | 0 |
| 2024 | 0 | 1 |
| 2025 | 1 | 1 |
By publication year.
Recent patents
- Compositions and methods for immunotherapy1 Apr 2025US 12,263,220 B2Memorial Sloan Kettering Cancer Center
- Compositions and methods for immunotherapy1 Aug 2023US 11,712,469 B2Memorial Sloan Kettering Cancer Center
- Compositions and methods for immunotherapy19 May 2020US 10,654,928 B2Memorial Sloan Kettering Cancer Center
- Stabilized soluble pre-fusion RSV F polypeptides21 May 2019US 10,294,279 B2Janssen Vaccines & Prevention B. V.
- Compositions and methods for immunotherapy12 Jun 2025US 2025/0186585 A1Memorial Sloan Kettering Cancer Center
- Compositions and methods for immunotherapy21 Mar 2024US 2024/0091353 A1Memorial Sloan Kettering Cancer Center
- Compositions and methods for immunotherapy8 Oct 2020US 2020/0317781 A1Memorial Sloan Kettering Cancer Center
- Stabilized soluble pre-fusion rsv f polypeptides23 Jun 2016US 2016/0176932 A1Crucell Holland B. V.
- Compositions and methods for immunotherapy3 Dec 2015US 2015/0342993 A1Memorial Sloan Kettering Cancer Center
Most cited
By later US patents